BASF Relocates Production of Kolliphor TPGS to its Minden Site
“Expanding the Kolliphor TPGS manufacturing capacity at our Minden site is another example of BASF’s commitment to the pharmaceutical and dietary supplement market. The relocation creates a more centralized production facility, reduces complexity in the production setup, and provides room for future expansion,” said Dr. Thorsten Schmeller, Head of Global Marketing New Products at BASF’s Global Business Unit Pharma Ingredients & Services. The Minden site has manufactured active pharmaceutical ingredients (APIs) and excipients under cGMP for more than 70 years and is regularly inspected by the FDA and European health authorities. Schmeller: “Thanks to the ICH Q7 quality management standards at our Minden site, we will be able to offer a Kolliphor TPGS grade that fulfills the requirements of an API.”
Commitment to a seamless transition
Until the production in Minden is fully operational, BASF will continue to manufacture Kolliphor TPGS at the Kankakee site, which will fully support pharmaceutical and nutraceutical customers during the transition. “We have scheduled a generous supply overlap that we expect allows for a seamless transition,” added Schmeller. “Our projection also takes into account the appropriate qualification period required to transition products used in pharmaceutical applications.” Kolliphor TPGS production at the Minden site is expected to start in the first quarter of 2013.
The Kankakee site remains an important production facility for BASF’s nutrition and health business. Besides food ingredients, the company manufactures ingredients for soaps, shampoos, detergents, coatings, inks and adhesives at the site.
Kolliphor TPGS is a water-soluble derivative of vitamin E that can directly enhance the bioavailability of poorly soluble active substances. It is commonly used in pharmaceutical and nutritional formulations, but also in cosmetics. Additionally it has plasticizing effects that are very beneficial for emerging platform technologies in the pharmaceutical industry such as hot melt extrusion (HME).
About Nutrition & Health
BASF’s Nutrition & Health division develops, produces and markets a comprehensive range of products and services for the pharmaceuticals, aroma chemicals, human nutrition and animal nutrition industries. The division addresses customer needs and enhances consumers’ well-being and quality of life. The division provides the pharmaceutical industry with active ingredients such as caffeine and ibuprofen, as well as excipients and customized synthesis services. Nutrition & Health produces aroma chemicals such as citral and geraniol for the flavor and fragrance industry. Important human nutrition products are vitamins and carotenoids, plant sterols, emulsifiers and omega-3 fatty acids. Its feed additives such as vitamins, carotenoids and enzymes make Nutrition & Health a worldwide leader for the animal nutrition market.
BASF is the world’s leading chemical company: The Chemical Company. Its portfolio ranges from chemicals, plastics, performance products and crop protection products to oil and gas. We combine economic success, social responsibility and environmental protection. Through science and innovation we enable our customers in almost all industries to meet the current and future needs of society. Our products and system solutions contribute to conserving resources, ensuring healthy food and nutrition and helping to improve the quality of life. We have summed up this contribution in our corporate purpose: We create chemistry for a sustainable future. BASF posted sales of about €73.5 billion in 2011 and had more than 111,000 employees as of the end of the year. BASF shares are traded on the stock exchanges in Frankfurt (BAS), London (BFA) and Zurich (AN). Further information on BASF is available on the Internet at www.basf.com